RNA on the outside of cells is no longer a fringe idea. Over the past several years, several groups have shown that RNAs can be modified with N-glycans and displayed on the surfaces of living cells, that surface RNAs help control neutrophil recruitment, and that RNA-binding proteins and glycoRNAs form domains on the membrane that other molecules exploit for entry. What has remained unclear is which specific RNA species sit on which primary immune cells, and whether they do anything functional. Answering that question for rare primary cell populations demanded new tools, and the team developed methods to profile, image and quantify surface RNAs in cells that are available only in limited numbers from patient blood.

Using these approaches, the researchers found that members of the Y RNA family, small noncoding RNAs encoded in the genome and classically bound by the Ro60 autoantigen, preferentially localize to the surface of human monocytes, the circulating precursors of macrophages that stand at the front line of innate immunity. Confocal and super-resolution imaging of live cells, using fluorescent DNA probes complementary to RNY1, RNY3, RNY4 and RNY5 in an intact-surface FISH protocol, showed Y RNA signal colocalizing with plasma membrane markers. Flow cytometry confirmed that monocytes and B cells carry far more surface Y RNA signal than T cells, and transcriptomic comparison of surface-Y-RNA-positive versus negative monocytes revealed that the positive fraction expressed higher levels of membrane protein genes and interleukin and chemokine transcripts.

The clinical hook came from an exploratory pooled cohort of patients with inflammatory bowel disease. The proportion of peripheral monocytes positive for surface Y RNAs was markedly higher in patients with Crohn’s disease or ulcerative colitis than in healthy donors or individuals with irritable bowel syndrome. The separation was strong enough that the surface-Y-RNA-positive monocyte ratio performed well as a diagnostic discriminator, with a receiver operating characteristic area under the curve of 0.924, a cutoff of 0.17, sensitivity of 0.815 and specificity of 0.900. B cells from the same patients also showed elevated frequencies of surface-Y-RNA-positive cells, though the monocyte signal was the more striking separator between inflammatory bowel disease and the non-inflammatory controls.

Correlation is not mechanism, so the team went after what these surface RNAs actually do. A key clue came from extracellular histones, the DNA-packaging proteins that escape from dying cells and circulate as damage-associated molecular patterns. Histones are known to drive lethal inflammation in sepsis and organ injury largely through the Toll-like receptors TLR2 and TLR4, and neutrophil extracellular trap density correlates with histopathological severity in Crohn’s disease. The researchers found that fluorescently labeled histones bound abundantly to monocytes, and that this binding collapsed when surface RNAs were destroyed with RNase A and T1 or removed with a targeted depletion strategy. Strikingly, the same treatments had no effect on histone binding to B cells or other peripheral blood mononuclear cells, pointing to a monocyte-specific, RNA-dependent capture mechanism.

Biochemistry supported a direct interaction. A modified RNA interacting protein capture assay identified histones among the proteins associated with surface Y RNA, and purified assays showed that Y5 RNA binds the H2A-H2B and H3-H4 histone complexes with saturable kinetics, confirmed by gel shift experiments. In other words, Y RNAs appear to act as membrane-tethered adapters that grab extracellular histones and hold them at the monocyte surface, positioning them for recognition by innate immune receptors.

Downstream of that capture, the consequences are inflammatory. When monocytes or THP-1 macrophage-like cells were stimulated with histones, IL6 mRNA and secreted IL-6 protein rose sharply. Silencing RNY1, RNY3, RNY4 or RNY5 with antisense oligonucleotides, degrading surface RNA with RNase A and T1, or blocking TLR signaling with the inhibitor sparstolonin B all blunted that induction, while control oligonucleotides did not. Reporter and signaling assays traced the effect to activation of NF-κB and AP-1, the canonical transcriptional drivers of inflammatory cytokine output. Super-resolution imaging added a spatial dimension: Y RNAs accumulated in the same membrane nanoclusters as TLR4 and TLR2, but not with unrelated membrane proteins such as CD98, TLR5 or TLR10, and preincubating histones with in vitro-transcribed Y RNAs disrupted their colocalization with TLR4, consistent with a competition for binding that maps onto the RNA-histone interface.

The therapeutic implication was tested in the standard dextran sulfate sodium model of colitis. The team developed a depletion strategy, dubbed HASTE, that combines antisense oligonucleotides complementary to Y RNAs with RNase H to eliminate surface Y RNAs without needing to transfect cells. In vitro validation on gel and in human peripheral blood mononuclear cells confirmed that the approach selectively removed surface Y RNA signal while sparing unrelated surface RNAs such as MT-RNR2 and XIST. In mice with DSS-induced colitis, in vivo HASTE efficiently eliminated surface Y RNAs from monocytes, and treated animals showed ameliorated disease activity compared with mice receiving a control antisense oligonucleotide. B cell function appeared largely untouched, since depleting surface Y RNAs did not detectably alter apoptosis or necrosis in anti-IgM-stimulated primary B cells, and the damage-associated molecule HMGB1 still induced IL6 in a Y-RNA-independent manner, suggesting the mechanism is comparatively specific to histone sensing.

The study arrives amid a rapid expansion of interest in cell-surface RNA biology, from the discovery of glycoRNA to reports that surface RNAs form ternary complexes with RNA-binding proteins and heparan sulfate to recruit immune receptors, and that glycoRNA complexed with heparan sulfate regulates VEGF-A signaling. Y RNAs themselves have a long history: they are required for chromosomal DNA replication in human cells, they are the RNA components of Ro60 ribonucleoprotein particles, and Ro60 requires Y3 RNA for cell surface exposure in the cardiac manifestations of neonatal lupus. The new work extends that autoimmunity connection into a mechanistic role in innate immune signaling, and the authors note that histones may also associate nonspecifically with membranes and that additional surface RNAs or cofactors may contribute to histone capture and presentation.

Several caveats temper the enthusiasm. The human cohort was exploratory and pooled, so the diagnostic performance of the surface-Y-RNA-positive monocyte ratio will need validation in larger, independent cohorts before it could inform clinical practice. The mouse experiments rely on a chemically induced colitis model, which recapitulates some but not all features of human inflammatory bowel disease. And the precise molecular architecture of the Y RNA-histone-TLR complex, including which RNA regions contact histones and how the nanoclusters assemble, remains to be resolved. Even so, the study establishes a concrete function for a specific RNA species on the surface of a primary immune cell, offers a plausible mechanistic bridge between cell death, extracellular histones and cytokine storm in the gut, and demonstrates that the amplifier can be silenced. Sequencing data from the human and mouse experiments are publicly available, and the analysis code has been released, giving the field the raw material to test how broadly this surface RNA logic extends across immunity.

Subject of Research: Cell-surface Y RNAs on human monocytes amplify histone-triggered innate immune signaling in inflammatory bowel disease

Article Title: Monocyte surface Y RNAs potentiate innate immunity

Article References: Jiang, X., He, W., Xu, C., Zheng, W., Li, C., Xu, D., Shao, Q., Li, Y., Liu, Z., Li, W., He, S., Wang, Z., Liu, R., Chu, Y., Luo, Z., Huang, X., Liu, J., Yang, E., & Hu, L. (2026). Monocyte surface Y RNAs potentiate innate immunity. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02100-w

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02100-w

Keywords: Y RNAs, monocytes, innate immunity, inflammatory bowel disease, extracellular histones, TLR2, TLR4, NF-κB, IL-6, glycoRNA, colitis, noncoding RNA

The study, published in the Journal of Translational Medicine, comes from a group led by Jingyuan Liu and Yang Liu at the Department of Radiotherapy of the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, with collaborators at the same institution and at Zhengzhou University’s First Affiliated Hospital. Their central finding is deceptively straightforward. In mouse models of non-small cell lung cancer liver metastasis, a prophylactic dose of just 2 Gray, delivered to the liver before metastatic challenge, significantly suppressed metastatic colonization. Among the doses tested, 2 Gy showed the strongest antimetastatic effect, a dose low enough that it causes minimal tissue damage yet high enough to fundamentally alter how the liver communicates with the immune system.

What makes this result remarkable is the mechanism behind it. Radiation therapy is conventionally understood as a cytotoxic tool, a way of killing tumor cells with focused beams of high-energy photons. But over the past two decades, radiobiologists have come to appreciate that radiation does far more than damage DNA. At low doses, it can reprogram the behavior of cells in the irradiated field, altering the signals they send to immune cells. The Zhengzhou team set out to test whether such immune modulation could be harnessed prophylactically, not to destroy tumor cells directly, but to make the liver a hostile landing ground for them.

To answer this question, the researchers combined an unusually broad set of tools. They used bulk RNA sequencing to survey gene expression across irradiated liver tissue, single-cell RNA sequencing to resolve which individual cell types were responding, and in vitro functional assays to test the signaling pathways they uncovered. Finally, they performed in vivo neutralization experiments, blocking a key molecule with antibodies in living animals to confirm that the mechanism they had identified was genuinely responsible for the antimetastatic effect. This layered approach allowed them to trace a complete signaling chain from hepatocytes, the main functional cells of the liver, all the way to the recruitment of cytotoxic immune cells.

The chain begins with hepatocytes. When the liver received its 2 Gy dose, the team found that hepatocytes increased their production of serum amyloid A1, or SAA1, a protein more commonly associated with inflammatory responses. SAA1 then acted on a specific population of immune cells residing in or recruited to the liver: inflammatory monocytes. These monocytes, which in the context of an unprepared pre-metastatic niche can be co-opted by tumors to suppress immunity and scaffold metastatic growth, were instead pushed in a fundamentally different direction by the irradiation-induced signal.

At the molecular level, SAA1 engaged Toll-like receptor 2, a pattern-recognition receptor best known for detecting microbial components, on the surface of the monocytes. Engagement of TLR2 activated a transcriptional program driven by the NF-κB pathway, specifically through its RELA subunit, a master regulator of inflammatory gene expression. The consequence of this activation was the upregulation of SLC7A11, a solute carrier protein that imports cystine into cells and is a central component of cellular antioxidant defenses. With SLC7A11 activity elevated, the monocytes achieved improved redox homeostasis, a better-balanced internal oxidative state that allowed them to sustain a new functional identity.

That identity was chemokine-secretory. The reprogrammed monocytes became robust producers of CXCL10, a chemokine with a well-established role in attracting cytotoxic immune cells. In the irradiated liver, CXCL10 served as a beacon, drawing CD8-positive T cells, the principal killer lymphocytes of the adaptive immune system, into the tissue that tumor cells would soon attempt to colonize. When circulating lung cancer cells arrived, they encountered a liver patrolled by an alert cytotoxic army rather than one paved with immunosuppressive stromal support. The pre-metastatic niche had been flipped from pro-metastatic to anti-metastatic.

The team did not stop at correlation. To prove that CXCL10 was functionally required for the protective effect, they neutralized the chemokine in irradiated animals. The result was decisive: blocking CXCL10 reduced the recruitment of CD8-positive T cells to the liver and attenuated, though did not necessarily abolish, the antimetastatic benefit of low-dose irradiation. This loss-of-function experiment anchors the entire mechanistic model. Without the chemokine signal, the reprogrammed monocytes lose their ability to summon cytotoxic T cells, and the liver reverts toward vulnerability. SLC7A11, meanwhile, was shown to be required to sustain the chemokine-secretory phenotype itself, placing the antioxidant transporter upstream of CXCL10 production in the causal chain.

The translational implications are considerable. Liver metastasis from lung cancer is a major driver of mortality, and current strategies for preventing it are limited. Immune checkpoint blockade has transformed outcomes for some patients with non-small cell lung cancer, but hepatic metastases are notoriously resistant to immunotherapy, in part because the liver’s immune environment is inherently tolerogenic. A prophylactic intervention that remodels the hepatic immune landscape before tumor cells arrive could, in principle, complement existing approaches. The dose involved, a single 2 Gy fraction, is far below the levels used for ablative radiotherapy and is comparable to fractions routinely delivered in palliative settings, suggesting that toxicity would be manageable, though this remains to be demonstrated in patients.

Caution is warranted. The findings come from mouse models, and the authors note that the published version is an early-release, peer-reviewed accepted manuscript subject to further editorial processing. The retrospective clinical component of the study was approved by the Ethics Committee of the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, and the animal work followed ARRIVE guidelines, but no prospective human trial data yet exist. Irradiating a healthy liver prophylactically raises legitimate questions that only clinical studies can answer, including optimal timing, patient selection, and long-term hepatic safety. Still, the study opens an intriguing frontier in what the authors describe as low-dose immune radiobiology: the idea that radiation, at doses far too low to kill tumor cells, can be deployed as an immune sculpting tool. If the hepatocyte-to-monocyte-to-CXCL10 axis identified here holds up in humans, a single low-dose treatment could one day help keep the liver off the map of metastatic destinations for lung cancer patients.

Subject of Research: Prophylactic low-dose liver irradiation reprogramming the pre-metastatic immune niche to suppress non-small cell lung cancer liver metastasis

Article Title: Prophylactic low-dose liver irradiation reprograms the pre-metastatic immune niche and suppresses NSCLC liver metastasis

Article References: Liu, J., Zhang, T., Zhu, X., Lan, Z., Li, L., Yang, Y., Wang, Q., Sun, Z., & Liu, Y. (2026). Prophylactic low-dose liver irradiation reprograms the pre-metastatic immune niche and suppresses NSCLC liver metastasis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08883-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08883-8

Keywords: low-dose irradiation, pre-metastatic niche, liver metastasis, NSCLC, SAA1, TLR2, NF-kappaB, SLC7A11, CXCL10, inflammatory monocytes, CD8 T cells, radiobiology

The work builds on a well-established precedent in bacterial immunology. FimH, an adhesion molecule from Escherichia coli, is known to activate immune cells including dendritic cells and T cells. Mfa1 plays an analogous adhesive role for P. gingivalis, the keystone pathogen of chronic periodontitis, but its immunostimulatory potential had not been thoroughly explored. To close that gap, the team synthesized and extracted recombinant Mfa1 from E. coli, giving them a purified protein they could test in controlled experiments without exposing animals or cells to the live pathogen.

The first line of evidence came from dendritic cells, the sentinels of the adaptive immune system. When bone marrow-derived dendritic cells from mice were exposed to recombinant Mfa1, the cells upregulated co-stimulatory molecules and major histocompatibility complex (MHC) molecules in a dose-dependent manner. These surface proteins are the molecular handshake through which dendritic cells license T cells: co-stimulatory molecules provide the activating signal, while MHC molecules present tumor or microbial antigens for T cell recognition. Their coordinated increase is a hallmark of dendritic cell maturation and a prerequisite for mounting a strong T cell response.

Those in vitro observations translated into living animals. When C57BL/6 mice received Mfa1, the proportion and absolute number of dendritic cells in the spleen increased, and the cells showed enhanced expression of C-C chemokine receptor type 7, or CCR7. CCR7 is the trafficking receptor that guides mature dendritic cells from peripheral tissues to lymph nodes, where they present antigen to naive T cells, so its upregulation is a functional indicator of dendritic cell migration and maturation rather than a mere surface marker change. Mfa1 treatment also elevated the numbers of the two principal conventional dendritic cell subsets, cDC1 and cDC2, further upregulated co-stimulatory and MHC molecules, and raised levels of pro-inflammatory cytokines in vivo, painting a picture of systemically awakened antigen-presenting machinery.

To identify the receptor through which Mfa1 exerts these effects, the researchers turned to computational structural biology. Using AI-based protein complex prediction together with all-atom molecular dynamics simulations, they modeled the interaction of Mfa1 with Toll-like receptors, the innate immune sensors that recognize microbial molecular patterns. The simulations showed that Mfa1 binds TLR2 with high structural confidence and stability, while its binding to TLR4 was markedly less stable. This kind of integrated modeling approach allows researchers to rank candidate receptor interactions before committing to lengthy experimental validation, and here it produced a clear, testable prediction.

The prediction held up under genetic scrutiny. The immune-activating effects of Mfa1 that were readily observed in wild-type mice were absent in TLR2-knockout mice, confirming that the protein’s activity depends on TLR2 signaling. This loss-of-function experiment is the mechanistic anchor of the study: it demonstrates that Mfa1 is not a nonspecific irritant but a ligand that engages a defined innate immune receptor, triggering the downstream maturation program in dendritic cells that the team had characterized in detail.

With innate immunity activated, the question became whether the response extended to the adaptive arm. Repeated Mfa1 treatment enhanced the intracellular production of two signature inflammatory cytokines, interferon-gamma and tumor necrosis factor-alpha, in both CD4-positive helper T cells and CD8-positive cytotoxic T cells. Interferon-gamma is a central coordinator of anti-tumor immunity, activating macrophages and increasing antigen presentation, while tumor necrosis factor-alpha contributes directly to inflammatory tumor cell killing. Robust cytokine production by both T cell compartments indicates that Mfa1-driven dendritic cell maturation successfully translates into T cell activation, the effector arm that checkpoint blockade therapies are designed to unleash.

The culmination of the study came in a Lewis lung carcinoma model, a widely used preclinical system for lung cancer immunotherapy. When the researchers combined Mfa1 with an anti–PD-L1 antibody, the checkpoint inhibitor’s anti-tumor efficacy was enhanced. Anti–PD-L1 antibodies work by blocking the interaction between PD-L1 on tumor or immune cells and PD-1 on T cells, releasing a molecular brake on T cell activity. But many tumors respond poorly to this class of drug, often because the immune system has not been sufficiently primed to recognize and attack the tumor in the first place. An adjuvant like Mfa1, which expands and matures dendritic cell populations and drives T cell activation, addresses that priming deficit and can convert a cold, unresponsive tumor microenvironment into one more receptive to checkpoint blockade.

The implications reach beyond lung cancer. Immune adjuvants are a critical but underdeveloped component of cancer immunotherapy, and most current options are synthetic or highly engineered molecules. A bacterial adhesion protein that engages TLR2, a receptor with a well-characterized role in immune activation, offers a biologically grounded scaffold for adjuvant design. The authors suggest that Mfa1 may serve as a potential immunostimulatory adjuvant to enhance cancer immunotherapy, and the combination of computational receptor prediction, genetic validation and efficacy testing in a tumor model provides a coherent proof-of-concept chain from molecule to mechanism to therapeutic outcome.

Considerable work remains before any clinical translation. The findings are confined to mouse models, and the dose, schedule, safety profile and immunogenicity of a recombinant bacterial protein in humans would require extensive evaluation. There is also an inherent irony to navigate: P. gingivalis is a destructive periodontal pathogen, and any therapeutic use of its components must ensure that adhesive or inflammatory properties relevant to infection are not transferred to patients. Nevertheless, the study adds Mfa1 to a growing list of microbial molecules being repurposed for immunotherapy, and it demonstrates how AI-guided structural prediction can accelerate the identification of immune receptor ligands. For a field searching for ways to make checkpoint inhibitors work in more patients, a protein from an unlikely oral microbe has emerged as a candidate worth watching.

Subject of Research: Immunostimulatory effects of the Porphyromonas gingivalis adhesion protein Mfa1 as an adjuvant for anti–PD-L1 cancer immunotherapy

Article Title: Porphyromonas gingivalis adhesion protein Mfa1 enhances the anti-cancer effect of anti–PD-L1 antibody by immune activation

Article References: An, E.-K., Zhang, W., Jung, M., Park, H.-B., Kim, S.-J., Ryu, D., Jeong, E., Lee, M., Xu, Y., Lee, P. C. W., Im, W., & Jin, J.-O. (2026). Porphyromonas gingivalis adhesion protein Mfa1 enhances the anti-cancer effect of anti–PD-L1 antibody by immune activation. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04587-6

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04587-6

Keywords: Mfa1, Porphyromonas gingivalis, TLR2, dendritic cells, anti–PD-L1, immune adjuvant, cancer immunotherapy, T cell activation, lung carcinoma, molecular dynamics simulation, CCR7, interferon-gamma

The study, published in the journal Molecular Diversity by Nashwa H. Zaher and Reham M. M. El-Hazek of the National Center for Radiation Research and Technology at the Egyptian Atomic Energy Authority, together with Mohamed I. Mostafa of Cairo University’s Faculty of Veterinary Medicine, set out to do something that plain thymoquinone has struggled to accomplish on its own. Although thymoquinone has attracted wide interest for its anti-inflammatory and antioxidant credentials, the natural molecule suffers from limitations that include poor drug-like behavior and instability. Rather than testing the parent compound, the researchers designed and synthesized thirteen novel disubstituted thymoquinone analogues, recrystallized them, and verified their structures using microanalytical and spectral data before any biological work began.

The strategic target of the investigation was the toll-like receptor family, and in particular TLR4, a pattern-recognition receptor of the innate immune system that has emerged as a central culprit in diabetic kidney disease. TLR4, which normally alerts the body to bacterial lipopolysaccharide through its MD-2 co-receptor, becomes inappropriately activated in the diabetic kidney milieu, where it promotes podocyte injury, interstitial fibrosis and the release of inflammatory cytokines. Its sister receptor TLR2 has likewise been linked to renal apoptosis. Blocking these receptors pharmacologically is therefore considered a rational strategy for interrupting the inflammatory cascade that converts metabolic stress into scarred, failing kidney tissue.

When the thirteen analogues were screened for their ability to inhibit TLR-4 activity, one compound separated itself decisively from the pack: a disubstituted propyl ether designated TQ13. The molecular logic behind the design reflects a broader trend in medicinal chemistry, in which ether linkages and lipophilic substituents are grafted onto natural product scaffolds to tune solubility, membrane permeability and target engagement. Ether prodrug and derivative strategies have been used elsewhere to improve the performance of natural molecules, and the Egyptian team’s approach of systematically varying disubstitution on the thymoquinone core allowed a direct structure-activity comparison across the series.

With the most potent inhibitor in hand, the researchers moved from the screening stage into live-animal testing. TQ13 was administered in a rat model of streptozotocin-induced hyperglycemia, the standard experimental approximation of diabetic metabolic derangement in which the toxin destroys insulin-producing beta cells and sends blood glucose soaring. Over the course of the in vivo investigations, the compound demonstrated a remarkably broad pharmacological profile: anti-hyperglycemic effects that tempered the metabolic insult itself, antioxidant activity that countered the oxidative stress characteristic of diabetic tissue, anti-inflammatory action consistent with its receptor-blocking design, and antiapoptotic effects that suggested protection of kidney cells from programmed death.

Crucially, the beneficial molecular effects translated into measurable protection of kidney function. Rats receiving TQ13 showed amelioration of kidney function markers, the clinical laboratory values that physicians use to gauge renal health and that typically deteriorate as diabetic nephropathy advances. Activity of both TLR2 and TLR4, the two toll-like receptors most consistently implicated in diabetic kidney injury, was reduced in the treated animals, supporting the idea that the compound’s renoprotection flows at least in part from quieting innate immune signaling in the kidney.

One unusual feature of the study deserves particular attention: the radiation stability of the new compound. The work emerges from a drug radiation research department, and the authors describe TQ13 as a radio-stable renoprotective candidate. Radiation stability matters for practical reasons that extend well beyond the laboratory. Many pharmaceutical products are sterilized by gamma or electron beam irradiation, and a molecule that degrades under such treatment presents formulation and regulatory headaches. A thymoquinone derivative that withstands radiolytic stress could, in principle, be processed and sterilized without sacrificing its chemical integrity, an advantage the authors highlight alongside its therapeutic potential.

The findings arrive amid a widening search for alternatives to the limited pharmacopoeia of diabetic kidney disease. Recent research has explored everything from mesenchymal stem cell therapy and nanoparticle delivery of TLR4-targeting genetic material to a roster of natural products that modulate toll-like receptor signaling. Thymoquinone itself has previously shown renoprotective effects through mechanisms involving the NOX2 and Nrf2 pathways, and it has been reported to downregulate TLR2 and TLR4 in models of rheumatoid arthritis and to regulate microglial polarization after brain ischemia via TLR4 signaling. The new work builds on that foundation but shifts the paradigm from testing a raw natural product to engineering derivatives with improved drug-like properties, following structure-activity strategies previously applied to thymoquinone analogues in other therapeutic areas such as oncology.

The authors are careful to frame their results as an early step rather than a finished medicine. They note that TQ13 may represent a promising candidate in diabetic nephropathy therapeutics but emphasize that more tentative studies on toxicity and on the exact mechanism of action are needed, including investigation of advanced staging pathways of the disease. Translational distance remains substantial: the evidence so far comes from receptor screening and a rodent model, and the gulf between streptozotocin-induced hyperglycemia in rats and human diabetic nephropathy, with its years of gradual glomerular remodeling, is one that many encouraging candidates have failed to cross.

Even with those caveats, the study offers a textbook illustration of how natural product chemistry, immunology and radiation science can converge on an unmet clinical need. Diabetic nephropathy continues to increase in prevalence worldwide, accompanied by rising rates of death and cardiovascular complications, and the absence of any approved drug dedicated exclusively to the condition represents a glaring gap in modern medicine. A rationally designed, structurally verified, radiation-stable derivative of a compound found in black cumin seed oil that simultaneously tames hyperglycemia, oxidative stress, inflammation, apoptosis and toll-like receptor activity is exactly the kind of multi-targeted candidate that the field has been seeking. Whether TQ13 can survive the rigor of toxicology, pharmacokinetics and human trials remains to be seen, but the road from the black seed to the nephrology clinic has just become measurably more concrete.

Subject of Research: Evaluation of novel thymoquinone analogues as toll-like receptor inhibitors for diabetic nephropathy treatment

Article Title: Evaluation of toll-like receptor inhibition by novel thymoquinone analogues as potential remedy for diabetic nephropathy

Article References: Zaher, N. H., El-Hazek, R. M. M., & Mostafa, M. I. (2026). Evaluation of toll-like receptor inhibition by novel thymoquinone analogues as potential remedy for diabetic nephropathy. Molecular Diversity. https://doi.org/10.1007/s11030-026-11730-z

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11730-z

Keywords: diabetic nephropathy, thymoquinone, toll-like receptors, TLR4, TLR2, drug discovery, medicinal chemistry, kidney disease, antioxidants, black cumin, radiation stability, inflammation

Non-tuberculous mycobacteria, often abbreviated NTM, are environmental organisms that increasingly cause chronic and debilitating lung disease worldwide. Among them, Mycobacterium abscessus stands out as particularly menacing. It is naturally resistant to many standard antibiotics, it can form ropelike cords that shield it from engulfment by immune cells, and it thrives in patients with pre-existing lung damage such as bronchiectasis, cystic fibrosis, or pulmonary fibrosis. Treatment regimens typically stretch for many months, involve multiple toxic drugs, and frequently fail to eradicate the infection. Against this grim clinical backdrop, the question of how the immune system naturally fights M. abscessus has remained surprisingly underexplored, particularly with respect to γδ T cells, an unconventional lymphocyte population whose role in NTM infection had never been systematically characterized.

γδ T cells differ from the conventional αβ T cells that dominate textbook immunology. Rather than recognizing peptide fragments presented by major histocompatibility molecules, they respond rapidly to a wide range of stress signals and microbial products, earning them a reputation as a bridge between innate and adaptive immunity. A major subset of these cells produces interleukin-17A, a powerful inflammatory cytokine best known for recruiting neutrophils and shaping defenses at body surfaces. To determine whether these cells matter in M. abscessus infection, the researchers built a mouse model of pulmonary infection and mapped the immune landscape of lung tissue over the early days of disease using single-cell RNA sequencing, a technique that captures the gene expression profile of thousands of individual cells simultaneously.

The single-cell atlas revealed a striking pattern. As infection took hold, γδ T cells accumulated in the lung and expanded a population that expressed high levels of IL-17A. When the team removed γδ T cells entirely, using mice genetically engineered to lack them, the consequences were dramatic: bacteria persisted at far higher levels in the lungs and spleens, and lung inflammation worsened. Conversely, when γδ T cells were depleted in animals that had already cleared a first infection and were then re-challenged, the protective advantage of prior exposure evaporated. These experiments established γδ T cells as indispensable players in the early defense against M. abscessus, a finding that had not been demonstrated before for any non-tuberculous mycobacterial pathogen.

Delving deeper, the investigators identified IL-17A itself as the linchpin of this protective response. Mice unable to produce IL-17A lost much of their capacity to control the infection, and importantly, the defect traced back to the γδ T cells themselves. Without IL-17A signaling, the cells became less adept at recognizing the bacterium and lost much of their cytotoxic firepower. In an elegant series of transfer experiments, IL-17A-deficient γδ T cells failed to protect infected animals, whereas their normal counterparts succeeded. This revealed something unusual: IL-17A was not merely acting as a broadcast signal to other immune players but was required within the γδ T cells themselves, a cell-intrinsic requirement that underscores how tightly the cytokine and its producer are wired together during this infection.

The mechanism by which these cells actually kill the bacterium proved to be equally instructive. M. abscessus is an extracellular pathogen during key phases of infection, residing outside host cells in the airways and tissue spaces. The researchers found that IL-17A-positive γδ T cells eliminated extracellular bacteria through a granzyme B-dependent cytotoxic pathway. Granzyme B is a serine protease classically associated with the destruction of virus-infected or malignant cells, delivered through pore-forming perforin or other release mechanisms. Its deployment against free-living bacteria adds a new dimension to the antimicrobial portfolio of γδ T cells and explains how a lymphocyte population usually discussed in the context of autoimmunity and inflammation can act as a direct bactericidal weapon.

How, then, does the immune system know to mobilize these cells in the first place? The answer lies in a cascade that begins with Toll-like receptor 2, a pattern-recognition receptor on macrophages that detects components of the bacterial cell wall. When M. abscessus engaged TLR2 on lung macrophages, the macrophages responded by secreting two cytokines, interleukin-1β and interleukin-23. This cytokine pair is a well-known stimulus for IL-17 production in T cells, and in this context it drove both the expansion and the activation of the IL-17A-positive γδ T cell population. Blocking either IL-1β or IL-23 in infected mice diminished the γδ T cell response and impaired bacterial control, mapping out a complete signaling axis that runs from bacterial recognition through macrophage activation to lymphocyte mobilization and, ultimately, bacterial killing.

Perhaps the most clinically resonant aspect of the study concerns patients whose immunity depends on interferon-gamma, the canonical cytokine for defense against mycobacteria. A subset of individuals, particularly in Southeast Asia, develops autoantibodies that neutralize their own interferon-gamma, leaving them exquisitely vulnerable to disseminated NTM infections. Using single-cell RNA sequencing of peripheral blood cells from NTM patients, the researchers found evidence that anti-interferon-gamma autoantibodies compromise γδ T cell function in humans, mirroring what they observed in mice lacking the interferon-gamma receptor. Crucially, in mice engineered without functional interferon-gamma signaling, IL-17A-positive γδ T cells still conferred protection, and the same held true in a model combining M. abscessus infection with bleomycin-induced pulmonary fibrosis. In other words, this arm of immunity operates independently of the interferon-gamma axis and remains effective even in scarred, damaged lungs.

The implications for therapy are considerable. Current treatment of NTM disease relies almost entirely on antibiotics that the pathogen is adept at resisting, and there are no licensed immunotherapies that bolster host defenses. If the pathways defined in this study can be harnessed in patients, whether by stimulating IL-1β and IL-23 signaling, expanding protective γδ T cell populations, or delivering IL-17A-driven cytotoxic activity directly, clinicians could gain a means of strengthening the lung’s own antimicrobial machinery. Such approaches would be especially valuable for the growing population of patients with anti-interferon-gamma autoantibodies or structural lung disease, for whom conventional regimens offer diminishing returns. The researchers caution that translating mouse findings to the clinic will require careful work, particularly because IL-17A is also implicated in inflammatory conditions such as psoriasis and could carry safety risks if induced systemically. Nevertheless, the identification of a concrete, mechanistically defined cell type that can clear M. abscessus marks a genuine advance. It transforms γδ T cells from immunological bystanders into a promising therapeutic target, and it reframes the fight against antibiotic-resistant mycobacteria as a battle that the immune system, with the right encouragement, may be able to win on its own terms.

Subject of Research: The role of IL-17A-producing γδ T cells in controlling pulmonary Mycobacterium abscessus infection in mice.

Article Title: IL-17A-producing γδ T cells control pulmonary Mycobacterium abscessus infection in mice

Article References: Hu, X., Lin, S., Meng, W., Liu, H., Qin, Z., Wu, Z., Wan, Y., Ma, S., Yang, X., Yin, Z., Chu, Y., Zhang, W., Shao, L., & Lin, Y. (2026). IL-17A-producing γδ T cells control pulmonary Mycobacterium abscessus infection in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02466-5

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02466-5

Keywords: Mycobacterium abscessus, non-tuberculous mycobacteria, γδ T cells, IL-17A, interferon-gamma, granzyme B, TLR2, IL-1β, IL-23, pulmonary infection, immunology, antibiotic resistance

The findings, published in BMC Biology, connect population genetics with clinical infectious-disease research. The investigators examined the evolutionary history of IL-4, TLR2, CCL2 and SLC11A1, genes involved in regulating inflammation and the detection or control of invading pathogens. They then compared genetic variation in these genes with clinical outcomes among nearly 4,000 people in Italy who had tested positive for SARS-CoV-2 through the Italian GEN-COVID study.

The evolutionary analysis used genetic data from more than 2,000 individuals representing African, European and Asian populations. The researchers searched for patterns consistent with natural selection, including differences in allele frequencies between populations and other signatures indicating that particular genetic variants had been favored or removed over time. All four genes showed evidence of evolutionary change, although the patterns differed across regions. That variation suggests that infectious diseases and other environmental pressures have shaped immune responses along distinct population histories.

Natural selection can act on immune genes in complex ways. A variant that improves resistance to one pathogen may increase the risk of excessive inflammation or another disease under different conditions. Immune genes are therefore often subject to balancing pressures rather than a single, universally beneficial genetic solution. The study’s results indicate that the versions of these genes common today may reflect long-term compromises between pathogen defense, inflammatory damage and changing environments.

The researchers also compared modern human sequences with genetic material from Neanderthals and Denisovans, extinct relatives of modern humans. Some shared variants may have been inherited from a common ancestor, while others could reflect interbreeding between ancient modern humans and these archaic populations. Such exchanges introduced genetic material into ancestral human populations tens of thousands of years ago, potentially including immune-related variants that influenced how later generations responded to infectious organisms.

These evolutionary signatures were established long before SARS-CoV-2 appeared. The coronavirus did not create the ancient patterns detected in the four genes; instead, it encountered immune systems already shaped by earlier infectious threats. “SARS-CoV-2, the coronavirus that causes COVID-19, may be new, but the immune system it encountered isn’t,” said Michael Campbell, an associate professor of biological sciences at USC Dornsife and the study’s senior author. The distinction is important because it frames COVID-19 susceptibility as a possible consequence of pre-existing biological variation rather than a response that evolved during the pandemic.

The clinical analysis produced a more recent and specific finding involving TLR2, which encodes Toll-like receptor 2. TLR2 is part of the innate immune system, the body’s rapid first line of defense against infection. It recognizes molecular patterns associated with microbes and activates signaling pathways that stimulate inflammatory responses. Two rare TLR2 variants were identified in the Italian COVID-19 dataset. One occurred more frequently among patients who had previously received organ transplants, while the other was associated with more severe COVID-19.

The transplant-related observation is notable because organ-transplant recipients already face elevated risks from COVID-19. Immunosuppressive medications used to prevent rejection can weaken antiviral defenses, while the underlying medical conditions of recipients may further increase vulnerability. A rare alteration in TLR2 could potentially add another layer of risk by changing pathogen recognition or downstream inflammatory signaling. However, the study does not establish that either variant causes severe disease, and the observed associations may be influenced by sample size, population structure or other clinical factors.

The researchers emphasize that the TLR2 results require replication in larger and more genetically diverse groups. Rare variants are particularly difficult to evaluate because they occur infrequently, meaning that even a study involving thousands of participants may contain only a small number of carriers. Independent cohorts, functional laboratory experiments and mechanistic studies will be needed to determine whether the variants alter TLR2 expression, protein activity or immune signaling during SARS-CoV-2 infection. Broader sampling will also help clarify whether the associations apply beyond the Italian population.

By combining evolutionary genomics with patient data, the study illustrates how ancient genetic history can guide investigations of modern viral disease. Genes shaped by past pathogens may contain clues to why individuals respond differently to the same infection, while rare mutations can reveal additional vulnerabilities that are invisible when researchers focus only on common variation. The authors say that this approach could eventually identify biological pathways useful for predicting disease risk or developing new preventive and therapeutic strategies, although such applications remain a future possibility rather than an immediate clinical outcome.

Subject of Research: People

Article Title: The evolutionary landscape of host immunity genes involved in respiratory and other immune-related diseases, and the identification of TLR2 variation associated with severe COVID-19

News Publication Date: 29-May-2026

Web References: https://doi.org/10.1186/s12915-026-02623-6

References: BMC Biology, DOI: 10.1186/s12915-026-02623-6

Keywords: COVID-19, SARS-CoV-2, TLR2, immune genes, evolutionary genetics, natural selection, rare genetic variants, severe disease, organ transplantation, infectious diseases